Sections
| Title | Starting Page | Number of Pages |
|---|
| Table of Contents | 2 | 40 |
| List of Tables | 36 | 5 |
| List of Figures | 41 | 1 |
| Introduction | 42 | 1 |
| Global Markets Direct Report Coverage | 42 | 1 |
| Head And Neck Cancer Overview | 43 | 1 |
| Therapeutics Development | 44 | 2 |
| Pipeline Products for Head And Neck Cancer Overview | 44 | 1 |
| Pipeline Products for Head And Neck Cancer Comparative Analysis | 45 | 1 |
| Head And Neck Cancer Therapeutics under Development by Companies | 46 | 14 |
| Head And Neck Cancer Therapeutics under Investigation by Universities/Institutes | 60 | 2 |
| Head And Neck Cancer Pipeline Products Glance | 62 | 4 |
| Late Stage Products | 62 | 1 |
| Clinical Stage Products | 63 | 1 |
| Early Stage Products | 64 | 1 |
| Unknown Stage Products | 65 | 1 |
| Head And Neck Cancer Products under Development by Companies | 66 | 21 |
| Head And Neck Cancer Products under Investigation by Universities/Institutes | 87 | 3 |
| Head And Neck Cancer Companies Involved in Therapeutics Development | 90 | 168 |
| 3SBio Inc. | 90 | 1 |
| 4SC AG | 91 | 1 |
| AB Science SA | 92 | 1 |
| AbbVie Inc | 93 | 1 |
| Accelerated Pharma, Inc. | 94 | 1 |
| Acceleron Pharma, Inc. | 95 | 1 |
| Adaptimmune Therapeutics Plc | 96 | 1 |
| Aduro BioTech, Inc. | 97 | 1 |
| Advaxis, Inc. | 98 | 1 |
| Advenchen Laboratories, LLC | 99 | 1 |
| Affimed GmbH | 100 | 1 |
| Alchemia Limited | 101 | 1 |
| Altor BioScience Corporation | 102 | 1 |
| Ambrx, Inc. | 103 | 1 |
| Amgen Inc. | 104 | 1 |
| arGEN-X BV | 105 | 1 |
| ArQule, Inc. | 106 | 1 |
| Aspyrian Therapeutics, Inc. | 107 | 1 |
| Astellas Pharma Inc. | 108 | 1 |
| AstraZeneca Plc | 109 | 1 |
| Atara Biotherapeutics, Inc. | 110 | 1 |
| ATLAB Pharma SAS | 111 | 1 |
| Aura Biosciences, Inc. | 112 | 1 |
| AVEO Pharmaceuticals, Inc. | 113 | 1 |
| Bayer AG | 114 | 1 |
| Betta Pharmaceuticals Co. Ltd. | 115 | 1 |
| Bexion Pharmaceuticals, LLC | 116 | 1 |
| Bio-Path Holdings, Inc. | 117 | 1 |
| BioDiem Ltd | 118 | 1 |
| Biomics Biotechnologies Co., Ltd. | 119 | 1 |
| Bionovis SA | 120 | 1 |
| BioNTech AG | 121 | 1 |
| Biotest AG | 122 | 1 |
| Boehringer Ingelheim GmbH | 123 | 1 |
| Boston Biomedical, Inc. | 124 | 1 |
| Bristol-Myers Squibb Company | 125 | 1 |
| Calithera Biosciences, Inc. | 126 | 1 |
| CEL-SCI Corporation | 127 | 1 |
| Celgene Corporation | 128 | 1 |
| Cell Medica Limited | 129 | 1 |
| Cellceutix Corporation | 130 | 1 |
| Celldex Therapeutics, Inc. | 131 | 1 |
| Celprogen, Inc. | 132 | 1 |
| Centrose LLC | 133 | 1 |
| Corvus Pharmaceuticals, Inc. | 134 | 1 |
| Cristal Therapeutics B.V. | 135 | 1 |
| Critical Outcome Technologies Inc. | 136 | 1 |
| CTI BioPharma Corp. | 137 | 1 |
| Daiichi Sankyo Company, Limited | 138 | 1 |
| DNJ Pharma, Inc. | 139 | 1 |
| Eisai Co., Ltd. | 140 | 1 |
| Eleven Biotherapeutics Inc. | 141 | 1 |
| Eli Lilly and Company | 142 | 1 |
| EntreChem, S.L. | 143 | 1 |
| Etubics Corporation | 144 | 1 |
| Eureka Therapeutics, Inc. | 145 | 1 |
| F. Hoffmann-La Roche Ltd. | 146 | 1 |
| Five Prime Therapeutics, Inc. | 147 | 1 |
| G&E Herbal Biotechnology Co., Ltd. | 148 | 1 |
| Genelux Corporation | 149 | 1 |
| GeneSegues Inc | 150 | 1 |
| Genexine, Inc. | 151 | 1 |
| Genmab A/S | 152 | 1 |
| Genticel S.A. | 153 | 1 |
| GlaxoSmithKline Plc | 154 | 1 |
| Gliknik, Inc. | 155 | 1 |
| Glycotope GmbH | 156 | 1 |
| Hanmi Pharmaceuticals, Co. Ltd. | 157 | 1 |
| Hookipa Biotech AG | 158 | 1 |
| Horizon Pharma Plc | 159 | 1 |
| Hutchison MediPharma Limited | 160 | 1 |
| Ignyta, Inc. | 161 | 1 |
| Immunomedics, Inc. | 162 | 1 |
| Immunovaccine, Inc. | 163 | 1 |
| Immunovative Therapies, Ltd. | 164 | 1 |
| Incuron, LLC | 165 | 1 |
| Incyte Corporation | 166 | 1 |
| Infinity Pharmaceuticals, Inc. | 167 | 1 |
| Innate Pharma S.A. | 168 | 1 |
| Inovio Pharmaceuticals, Inc. | 169 | 1 |
| InteRNA Technologies B.V. | 170 | 1 |
| IRX Therapeutics, Inc. | 171 | 1 |
| ISA Pharmaceuticals B.V. | 172 | 1 |
| Jiangsu Kanion Pharmaceutical Co., Ltd. | 173 | 1 |
| Johnson &Johnson | 174 | 1 |
| Kite Pharma Inc | 175 | 1 |
| Kolltan Pharmaceuticals, Inc. | 176 | 1 |
| Kura Oncology, Inc. | 177 | 1 |
| Laboratoires Pierre Fabre SA | 178 | 1 |
| Lakewood-Amedex Inc | 179 | 1 |
| Loxo Oncology, Inc. | 180 | 1 |
| Lytix Biopharma AS | 181 | 1 |
| Mabion SA | 182 | 1 |
| Mabtech Limited | 183 | 1 |
| MacroGenics, Inc. | 184 | 1 |
| Marsala Biotech Inc. | 185 | 1 |
| Mateon Therapeutics Inc | 186 | 1 |
| MaxiVAX SA | 187 | 1 |
| Meabco A/S | 188 | 1 |
| MedImmune, LLC | 189 | 1 |
| Merck &Co., Inc. | 190 | 1 |
| Merck KGaA | 191 | 1 |
| Merrimack Pharmaceuticals, Inc. | 192 | 1 |
| Millennium Pharmaceuticals Inc | 193 | 1 |
| Mirati Therapeutics Inc. | 194 | 1 |
| Molecular Partners AG | 195 | 1 |
| Moleculin Biotech Inc | 196 | 1 |
| Molplex Ltd. | 197 | 1 |
| NanoCarrier Co., Ltd. | 198 | 1 |
| Natco Pharma Limited | 199 | 1 |
| Neonc Technologies Inc | 200 | 1 |
| Northwest Biotherapeutics, Inc. | 201 | 1 |
| Novartis AG | 202 | 1 |
| Omnitura Therapeutics Inc. | 203 | 1 |
| Oncobiologics, Inc. | 204 | 1 |
| Oncolys BioPharma Inc | 205 | 1 |
| Oncolytics Biotech Inc. | 206 | 1 |
| Onconova Therapeutics, Inc. | 207 | 1 |
| OncoSec Medical Incorporated | 208 | 1 |
| Ono Pharmaceutical Co., Ltd. | 209 | 1 |
| Oryx GmbH &Co. KG | 210 | 1 |
| Panacea Biotec Limited | 211 | 1 |
| PCI Biotech Holding ASA | 212 | 1 |
| PDS Biotechnology Corporation | 213 | 1 |
| Pfizer Inc. | 214 | 1 |
| Pharma Mar, S.A. | 215 | 1 |
| Pique Therapeutics | 216 | 1 |
| PlantForm Corporation | 217 | 1 |
| Plexxikon Inc. | 218 | 1 |
| PNP Therapeutics, Inc. | 219 | 1 |
| Profectus BioSciences, Inc. | 220 | 1 |
| ProNAi Therapeutics, Inc. | 221 | 1 |
| Provectus Biopharmaceuticals, Inc. | 222 | 1 |
| R-Pharm | 223 | 1 |
| Redx Pharma Plc | 224 | 1 |
| Reliance Life Sciences Pvt. Ltd. | 225 | 1 |
| Sanofi | 226 | 1 |
| Sapvax | 227 | 1 |
| Sareum Holdings Plc | 228 | 1 |
| Selecta Biosciences, Inc. | 229 | 1 |
| Shanghai Henlius Biotech Co., Ltd. | 230 | 1 |
| Shenzen SiBiono GeneTech Co., Ltd. | 231 | 1 |
| Shionogi &Co., Ltd. | 232 | 1 |
| Silence Therapeutics Plc | 233 | 1 |
| Sillajen Biotherapeutics | 234 | 1 |
| Sinil Pharmaceutical Co., Ltd | 235 | 1 |
| SuviCa Inc. | 236 | 1 |
| Symphogen A/S | 237 | 1 |
| SynCore Biotechnology Co., Ltd. | 238 | 1 |
| Taiwan Liposome Company, Ltd. | 239 | 1 |
| Takara Bio Inc. | 240 | 1 |
| Takis S.r.l. | 241 | 1 |
| Tara Immuno-Oncology Therapeutics LLC | 242 | 1 |
| Tessa Therapeutics Pte Ltd | 243 | 1 |
| Theravectys SA | 244 | 1 |
| Tolero Pharmaceuticals, Inc. | 245 | 1 |
| TyrNovo Ltd. | 246 | 1 |
| UbiVac, LLC | 247 | 1 |
| Vaccibody AS | 248 | 1 |
| VasGene Therapeutics, Inc. | 249 | 1 |
| Vault Pharma Inc. | 250 | 1 |
| Vaxeal Holding SA | 251 | 1 |
| VentiRx Pharmaceuticals, Inc. | 252 | 1 |
| Virttu Biologics Limited | 253 | 1 |
| VLPbio | 254 | 1 |
| VM Discovery, Inc. | 255 | 1 |
| Vyriad Inc | 256 | 1 |
| Yabao Pharmaceutical Group Co., Ltd. | 257 | 1 |
| Head And Neck Cancer Therapeutics Assessment | 258 | 35 |
| Assessment by Monotherapy Products | 258 | 1 |
| Assessment by Combination Products | 259 | 1 |
| Assessment by Target | 260 | 14 |
| Assessment by Mechanism of Action | 274 | 15 |
| Assessment by Route of Administration | 289 | 2 |
| Assessment by Molecule Type | 291 | 2 |
| Drug Profiles | 293 | 821 |
| 4SC-205 Drug Profile | 293 | 2 |
| ABBV-221 Drug Profile | 295 | 1 |
| acalabrutinib Drug Profile | 296 | 3 |
| AdIL-24 Drug Profile | 299 | 2 |
| ADUS-100 Drug Profile | 301 | 3 |
| afatinib dimaleate Drug Profile | 304 | 13 |
| AFM-22 Drug Profile | 317 | 1 |
| AFM-24 Drug Profile | 318 | 1 |
| AlloVax Drug Profile | 319 | 2 |
| alpelisib Drug Profile | 321 | 3 |
| ALT-803 Drug Profile | 324 | 3 |
| amcasertib Drug Profile | 327 | 2 |
| AMG-319 Drug Profile | 329 | 2 |
| Antibodies to Inhibit FRMD4A for Oncology Drug Profile | 331 | 1 |
| Antisense Oligonucleotide to Target EGFR for Head and Neck Cancer Squamous Cell Carcinoma Drug Profile | 332 | 1 |
| Antisense RNAi Oligonucleotide for Nasopharyngeal Cancer Drug Profile | 333 | 1 |
| Antisense RNAi Oligonucleotide to Inhibit Mutated Ataxia Telangiectasia Gene for Head and Neck Cancer Drug Profile | 334 | 1 |
| apatinib Drug Profile | 335 | 3 |
| ARGX-110 Drug Profile | 338 | 4 |
| atezolizumab Drug Profile | 342 | 14 |
| ATL-101 Drug Profile | 356 | 2 |
| Atu-027 Drug Profile | 358 | 4 |
| AV-203 Drug Profile | 362 | 3 |
| avelumab Drug Profile | 365 | 5 |
| axalimogene filolisbac Drug Profile | 370 | 16 |
| AY-4 Drug Profile | 386 | 1 |
| azacitidine Drug Profile | 387 | 5 |
| AZD-1775 Drug Profile | 392 | 3 |
| AZD-6738 Drug Profile | 395 | 1 |
| AZD-9150 Drug Profile | 396 | 3 |
| baltaleucel-T Drug Profile | 399 | 2 |
| BAY-1163877 Drug Profile | 401 | 1 |
| BB-002 Drug Profile | 402 | 1 |
| Biologic for Oncology Drug Profile | 403 | 1 |
| BMS-986016 Drug Profile | 404 | 2 |
| BMX-001 Drug Profile | 406 | 1 |
| BNV-003 Drug Profile | 407 | 1 |
| BP-1001 Drug Profile | 408 | 6 |
| BPC-1 Drug Profile | 414 | 1 |
| buparlisib hydrochloride Drug Profile | 415 | 5 |
| BXQ-350 Drug Profile | 420 | 2 |
| cabazitaxel Drug Profile | 422 | 2 |
| cabazitaxel Drug Profile | 424 | 1 |
| cabiralizumab Drug Profile | 425 | 3 |
| capmatinib Drug Profile | 428 | 3 |
| CB-1158 Drug Profile | 431 | 2 |
| CBL-0137 Drug Profile | 433 | 4 |
| CBX-1 Drug Profile | 437 | 1 |
| CCP-040 Drug Profile | 438 | 1 |
| CCT-244747 Drug Profile | 439 | 2 |
| CCV-3612552 Drug Profile | 441 | 1 |
| Cellular Immunotherapy for HPV Associated Cancers Drug Profile | 442 | 1 |
| Cellular Immunotherapy for Multiple Sclerosis Drug Profile | 443 | 1 |
| Cellular Immunotherapy for Nasopharyngeal Cancer Drug Profile | 444 | 1 |
| Cellular Immunotherapy for Oncology Drug Profile | 445 | 3 |